Fidelity
US asset management giant; co-investor in CellCentric's £170m Series D.
Last refreshed: 13 May 2026
Timeline for Fidelity
CellCentric raises Europe's largest 2026 biotech round
UK Startups and Innovation- Why does Fidelity invest in private biotech rounds?
- Fidelity participates in late-stage private biotech rounds as a crossover investor, able to hold positions through IPO onto public markets. Its presence signals that a company's public-market story has been validated.Source: Lowdown uk-startups-and-innovation U#4
- How big is Fidelity Investments?
- Fidelity manages more than $14tn in assets across mutual funds, retirement accounts, and institutional investment, making it one of the largest privately held asset managers globally.Source: Fidelity
Background
Fidelity Investments (Fidelity Management & Research) is one of the largest privately held asset management firms in the world, headquartered in Boston, Massachusetts. Founded in 1946, Fidelity manages more than $14tn in assets across mutual funds, retirement accounts, brokerage, and institutional investment. It is known for its active equity management tradition, large research team, and significant participation in crossover (public-private) biotech and technology rounds. Fidelity is a major institutional participant in late-stage private financings — particularly in biotech — alongside its enormous public-market presence.
Fidelity participated in CellCentric's £170m Series D in May 2026, joining lead investor Venrock Healthcare Capital Partners, strategic co-investor Pfizer, and a range of specialist life-sciences VCs. Fidelity's presence as a crossover investor — able to hold the position through an IPO onto public markets — is a standard signal in late-stage biotech rounds that the company's public-market story has been stress-tested. CellCentric's Phase III programme for inobrodib in multiple myeloma and prostate cancer is approaching the datapoints that would support an IPO narrative.